Effect of m-chlorophenylpiperazine on plasma arginine-vasopressin concentrations in healthy subjects

René S. Kahn, Mitchel A. Kling, Scott Wetzler, Gregory M. Asnis, Herman van Praag

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

It has been demonstrated convincingly that ACTH and prolactin release are under the stimulatory control of serotonin (5-hydroxytryptamine, 5HT). Recent animal studies suggest that stimulation of 5HT activity also induces the release of arginine-vasopressin (AVP). More specifically, m-chlorophenylpiperazine (MCPP), a 5HT agonist widely used to examine 5HT receptor responsivity in human subjects, has been found to induce AVP release in rodents. This study examined whether MCPP increased plasma AVP levels in healthy human subjects. MCPP was administered orally to 17 healthy subjects in a placebo-controlled design in doses of 0.25 and 0.5 mg/kg. AVP was measured twice hourly over a 210 min period after administration of capsules. MCPP did not significantly alter AVP levels as compared to placebo. However, female subjects had significantly lower plasma AVP levels than males. Since it has been suggested that MCPP-induced AVP release in animals is due to stimulation of 5HT1c receptors, the fact that MCPP did not induce the release of AVP in humans suggests that either MCPP is not a potent 5HT1c agonist or that AVP is not released by stimulation of 5HT(1c) receptors in human subjects. The observation of gender differences in plasma AVP levels suggests that this factor should be taken into account in future studies of AVP secretion in plasma.

Original languageEnglish (US)
Pages (from-to)225-228
Number of pages4
JournalPsychopharmacology
Volume108
Issue number1-2
DOIs
StatePublished - Jul 1992

Fingerprint

Arginine Vasopressin
Healthy Volunteers
Serotonin
Serotonin Receptors
1-(3-chlorophenyl)piperazine
Placebos
Serotonin Receptor Agonists
Prolactin
Adrenocorticotropic Hormone
Capsules
Rodentia
Observation

Keywords

  • Arginine-vasopressin
  • Human
  • m-Chlorophenylpiperazine
  • Serotonin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of m-chlorophenylpiperazine on plasma arginine-vasopressin concentrations in healthy subjects. / Kahn, René S.; Kling, Mitchel A.; Wetzler, Scott; Asnis, Gregory M.; van Praag, Herman.

In: Psychopharmacology, Vol. 108, No. 1-2, 07.1992, p. 225-228.

Research output: Contribution to journalArticle

Kahn, René S. ; Kling, Mitchel A. ; Wetzler, Scott ; Asnis, Gregory M. ; van Praag, Herman. / Effect of m-chlorophenylpiperazine on plasma arginine-vasopressin concentrations in healthy subjects. In: Psychopharmacology. 1992 ; Vol. 108, No. 1-2. pp. 225-228.
@article{4d98aad989d24383aa27e45b624f726f,
title = "Effect of m-chlorophenylpiperazine on plasma arginine-vasopressin concentrations in healthy subjects",
abstract = "It has been demonstrated convincingly that ACTH and prolactin release are under the stimulatory control of serotonin (5-hydroxytryptamine, 5HT). Recent animal studies suggest that stimulation of 5HT activity also induces the release of arginine-vasopressin (AVP). More specifically, m-chlorophenylpiperazine (MCPP), a 5HT agonist widely used to examine 5HT receptor responsivity in human subjects, has been found to induce AVP release in rodents. This study examined whether MCPP increased plasma AVP levels in healthy human subjects. MCPP was administered orally to 17 healthy subjects in a placebo-controlled design in doses of 0.25 and 0.5 mg/kg. AVP was measured twice hourly over a 210 min period after administration of capsules. MCPP did not significantly alter AVP levels as compared to placebo. However, female subjects had significantly lower plasma AVP levels than males. Since it has been suggested that MCPP-induced AVP release in animals is due to stimulation of 5HT1c receptors, the fact that MCPP did not induce the release of AVP in humans suggests that either MCPP is not a potent 5HT1c agonist or that AVP is not released by stimulation of 5HT(1c) receptors in human subjects. The observation of gender differences in plasma AVP levels suggests that this factor should be taken into account in future studies of AVP secretion in plasma.",
keywords = "Arginine-vasopressin, Human, m-Chlorophenylpiperazine, Serotonin",
author = "Kahn, {Ren{\'e} S.} and Kling, {Mitchel A.} and Scott Wetzler and Asnis, {Gregory M.} and {van Praag}, Herman",
year = "1992",
month = "7",
doi = "10.1007/BF02245312",
language = "English (US)",
volume = "108",
pages = "225--228",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1-2",

}

TY - JOUR

T1 - Effect of m-chlorophenylpiperazine on plasma arginine-vasopressin concentrations in healthy subjects

AU - Kahn, René S.

AU - Kling, Mitchel A.

AU - Wetzler, Scott

AU - Asnis, Gregory M.

AU - van Praag, Herman

PY - 1992/7

Y1 - 1992/7

N2 - It has been demonstrated convincingly that ACTH and prolactin release are under the stimulatory control of serotonin (5-hydroxytryptamine, 5HT). Recent animal studies suggest that stimulation of 5HT activity also induces the release of arginine-vasopressin (AVP). More specifically, m-chlorophenylpiperazine (MCPP), a 5HT agonist widely used to examine 5HT receptor responsivity in human subjects, has been found to induce AVP release in rodents. This study examined whether MCPP increased plasma AVP levels in healthy human subjects. MCPP was administered orally to 17 healthy subjects in a placebo-controlled design in doses of 0.25 and 0.5 mg/kg. AVP was measured twice hourly over a 210 min period after administration of capsules. MCPP did not significantly alter AVP levels as compared to placebo. However, female subjects had significantly lower plasma AVP levels than males. Since it has been suggested that MCPP-induced AVP release in animals is due to stimulation of 5HT1c receptors, the fact that MCPP did not induce the release of AVP in humans suggests that either MCPP is not a potent 5HT1c agonist or that AVP is not released by stimulation of 5HT(1c) receptors in human subjects. The observation of gender differences in plasma AVP levels suggests that this factor should be taken into account in future studies of AVP secretion in plasma.

AB - It has been demonstrated convincingly that ACTH and prolactin release are under the stimulatory control of serotonin (5-hydroxytryptamine, 5HT). Recent animal studies suggest that stimulation of 5HT activity also induces the release of arginine-vasopressin (AVP). More specifically, m-chlorophenylpiperazine (MCPP), a 5HT agonist widely used to examine 5HT receptor responsivity in human subjects, has been found to induce AVP release in rodents. This study examined whether MCPP increased plasma AVP levels in healthy human subjects. MCPP was administered orally to 17 healthy subjects in a placebo-controlled design in doses of 0.25 and 0.5 mg/kg. AVP was measured twice hourly over a 210 min period after administration of capsules. MCPP did not significantly alter AVP levels as compared to placebo. However, female subjects had significantly lower plasma AVP levels than males. Since it has been suggested that MCPP-induced AVP release in animals is due to stimulation of 5HT1c receptors, the fact that MCPP did not induce the release of AVP in humans suggests that either MCPP is not a potent 5HT1c agonist or that AVP is not released by stimulation of 5HT(1c) receptors in human subjects. The observation of gender differences in plasma AVP levels suggests that this factor should be taken into account in future studies of AVP secretion in plasma.

KW - Arginine-vasopressin

KW - Human

KW - m-Chlorophenylpiperazine

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0026648597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026648597&partnerID=8YFLogxK

U2 - 10.1007/BF02245312

DO - 10.1007/BF02245312

M3 - Article

C2 - 1410142

AN - SCOPUS:0026648597

VL - 108

SP - 225

EP - 228

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1-2

ER -